TipRanks on MSN4d
AIM Vaccine Secures Approval for Advanced Rabies Vaccine, Bolstering Global Market PositionAn update from AIM Vaccine Co., Ltd. Class H ( ($HK:6660) ) is now available. AIM Vaccine Co., Ltd. has received approval from the National ...
There are two types of rabies vaccines: one is a serum-based rabies vaccine, and the other is a serum-free rabies vaccine. Currently, no serum-free rabies vaccine has been registered for market. The ...
As global capital flows positively into the pharmaceutical sector, PRC vaccine leader AIM Vaccine announced on February 26 that its self-developed mRNA RSV vaccine has recently received clinical trial ...
On February 23, PRC vaccine leader AIM Vaccine (06660.HK) announced that its self-developed mRNA shingles vaccine has recently been submitted for clinical approval to the U.S. Food and Drug ...
Aim Vaccine Co. Ltd. may become the first company to gain regulatory clearance of a prophylactic iterative serum-free human rabies vaccine. Beijing-based Aim said it is preparing a regulatory ...
HONG KONG, Feb. 12, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed ...
On-demand video webcast now availableIncludes latest updates on pancreatic cancer and bird flu clinical trialsOCALA, Fla., March 11, 2025 ...
Expect efforts to discredit ACIP by portraying medical and public health experience as bias rather than the result of decades ...
On February 23, PRC vaccine leader AIM Vaccine (06660.HK) announced that its self-developed mRNA shingles vaccine has recently been submitted for clinical approval to the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback